Fig. 1: SIRT1 is aberrantly upregulated in KRASMut NSCLC cell lines and tumors. | Experimental & Molecular Medicine

Fig. 1: SIRT1 is aberrantly upregulated in KRASMut NSCLC cell lines and tumors.

From: Oncogenic KRAS mutation confers chemoresistance by upregulating SIRT1 in non-small cell lung cancer

Fig. 1

A SIRT1 protein expression was measured in one noncancerous lung epithelial cell line (BEAS-2B), five KRASMut cell lines (H358, H460, NCIH23, SKLU-1, and SW960), a KRASMut/EGFRMut cell line (H1650), five KRASWT/EGFRWT cell lines (HCC1666, H322M, H522, Calu-3, and H1650), and three EGFRMut cell lines (H1975, HCC827, and HCC2279). The area density of each band was measured with ImageJ software. The data were normalized to actin and are presented as the ratio with respect to the area density of actin. The data are plotted relative to the values obtained in the BEAS-2B cell line with SIRT1 expression. Student’s t test, mean ± SD; n = 3; *p < 0.05. B Representative immunohistochemical staining for SIRT1 and H&E staining in KrasLA2_WT and KrasLA2_G12D Tg mouse lungs at 16 weeks of age. Representative images are shown. Scale bar, 100 μm. The high-magnification images correspond to the areas marked by the black box. C SIRT1 mRNA expression was measured by quantitative real-time PCR in the same cell lines shown in Fig. 1A. RPL32 was used as an internal control and for normalization. Student’s t test, mean ± SD; n = 3; *p < 0.05. D The mRNA expression of Sirt1 was measured by RT‒qPCR in cancerous and adjacent noncancerous lung tissues of KrasLA2_G12D Tg mice. Rpl32 was used as an internal control and for normalization. Student’s t test, mean ± SEM; n = 3; *p < 0.05.

Back to article page